NCT06993844 2026-03-17Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsEnsem TherapeuticsPhase 1/2 Recruiting233 enrolled
NCT01968109 2026-01-06An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsBristol-Myers SquibbPhase 1/2 Completed1,482 enrolled 56 charts
NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA